Meta-Analysis
Copyright ©The Author(s) 2023.
World J Diabetes. Oct 15, 2023; 14(10): 1573-1584
Published online Oct 15, 2023. doi: 10.4239/wjd.v14.i10.1573
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of this indirect meta-analysis.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 The forest plot exhibiting pooled effect estimates and indirect comparison between chiglitazar and thiazolidinediones on efficacy endpoints including hemoglobin A1c, fasting blood glucose, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, homeostasis model assessment of insulin resistance, homeostasis model assessment of β cell function, alanine aminotransferase and aspartate aminotransferase. HbA1c: Hemoglobin A1c; FBG: Fasting blood glucose; TG: Triglycerides; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cell function; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; RR: Risk ratios; 95%CI: 95% confidential intervals; TZD: Thiazolidinedione.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 The forest plot exhibiting pooled effect estimates and indirect comparison between chiglitazar and thiazolidinediones on safety endpoints including weight gain, hypoglycemia, edema, bone fractures, upper respiratory tract infection and urinary tract infection. HbA1c: Hemoglobin A1c; FBG: Fasting blood glucose; TG: Triglycerides; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cell function; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; RR: Risk ratios; 95%CI: 95% confidential intervals; TZD: Thiazolidinedione.